Ciprid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciprid

Quick Facts about Ciprid (Sucralfate)

Property Description
Active ingredient Sucralfate (INN)
Form Tablet, Oral Suspension
Pharmacological class Antiulcer Agent / Mucosal Protectant
Common function Creates a physical protective barrier over ulcers
Origin Synthetic (aluminum salt of sulfated disaccharide)

What Type of Medicine is Ciprid (Sucralfate)?

Ciprid is a pharmaceutical preparation whose active ingredient is Sucralfate, a unique medication classified as an Antiulcer Agent and specifically recognized as a Mucosal Protectant. Its primary function is to work locally within the upper gastrointestinal tract to protect injured tissue, making it a non-systemic drug generally available by prescription. As a gastrointestinal agent, its function is localized rather than systemic.

This classification distinguishes it from other common acid-reducing drugs, such as proton pump inhibitors or H2-receptor antagonists, which focus on altering acid production. Ciprid offers a distinct, alternative approach by acting as a physical barrier to promote natural healing processes.


Composition and Forms: Is Ciprid Natural or Synthetic?

As a single-ingredient medicine, the active compound, Sucralfate, is a synthetic ingredient, chemically synthesized as an aluminum salt of sulfated disaccharide, a complex derivative of sucrose. Sucralfate is used orally and is supplied in two main forms: a solid tablet and an oral suspension. The availability of the oral suspension is often preferred for more direct contact with mucosal surfaces in the upper digestive tract.


What is the General Purpose of a Mucosal Protectant?

The general purpose of Ciprid is to create a protective bandage over areas of damage, such as ulcers, in the stomach or duodenum. This function begins when Sucralfate encounters the stomach's acid, transforming it into a sticky substance that selectively adheres to the exposed protein found at ulcer sites. The resulting physical barrier shields the injured tissue from aggressive digestive agents, including hydrochloric acid, the enzyme pepsin, and bile salts, thereby minimizing further irritation and supporting the body's intrinsic mechanism for repair.

Regulatory References

  1. NIH DailyMed Drug Information

What side effects are possible with Ciprid?

Possible Side Effects and Safety Information

The official safety profile for Ciprid (Sucralfate) is primarily defined by its local action within the gastrointestinal tract, leading to a specific pattern of adverse reactions documented in regulatory sources.

Frequency and System-Organ Classifications

The most frequent documented adverse reaction is constipation, reported in 2% of patients in clinical trials. Other, less frequent effects (incidence less than 0.5%) are classified across several body systems, including Gastrointestinal Disorders (e.g., diarrhea, dry mouth, nausea) and Nervous System Disorders (e.g., dizziness, insomnia, headache). Dermatological reactions like rash and pruritus are also documented as infrequent.

Serious Adverse Reactions and Safety Constraints

Official labeling documents emphasize several important safety considerations. A documented risk is bezoar formation, primarily in patients with underlying conditions that affect gastric motility. Since Sucralfate is an aluminum-containing compound, patients with chronic renal failure require particular caution due to the potential for aluminum accumulation, which can lead to serious toxicity such as encephalopathy or osteomalacia.

Furthermore, the oral suspension form is strictly for oral use only. Fatal complications, including pulmonary and cerebral emboli, have been documented following inappropriate intravenous administration. Post-marketing reports also include serious hypersensitivity reactions, such as anaphylactic reactions and various forms of edema.

Overdose and Emergency Response

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations: Acute oral overdose is commonly asymptomatic; reported symptoms are non-specific and primarily gastrointestinal: dyspepsia, abdominal pain, nausea, and vomiting.
Physiological systems affected: The Gastrointestinal system for acute symptoms. The Skeletal and Central Nervous System (CNS) for chronic exposure due to aluminum toxicity.
Dose-related or exposure-related factors: Acute oral toxicity risk is minimal due to poor absorption. Severe risk is tied to chronic, high total body burden of aluminum.
Population-specific overdose notes: Patients with chronic renal failure or on dialysis are at high risk due to impaired aluminum excretion, potentially leading to severe outcomes like encephalopathy and osteodystrophy.
Emergency-response statements: The official action is to seek emergency medical attention. The regulatory instruction is to contact the Poison Control Center immediately.
When immediate medical help is required: Immediate medical help is required upon suspected overdosage, as mandated by the instruction to seek emergency medical attention.

Overdose Classifications (High-Level)

Classification Element Official Regulatory Description
Severity classification: Acute oral overdosage risk is classified as minimal. Severe complications are associated with chronic aluminum accumulation in a susceptible population.
Overdose-context constraints: Due to limited experience in humans, no specific treatment recommendations are given. Management procedures are generally supportive.

Resulting Overdose Structure

Official overdose statements: • No specific antidote or treatment regimen is officially recommended for acute overdose. • The mandated action is to seek emergency medical attention and contact a Poison Control Center immediately. • Severe outcomes are officially documented: aluminum osteodystrophy, osteomalacia, and encephalopathy, linked to chronic aluminum exposure in patients with chronic renal failure.

Connection to the overall overdose profile: Regulatory documents define the Sucralfate overdose profile by highlighting the minimal acute systemic risk due to poor absorption, contrasting this with the severe, officially documented risk of aluminum toxicity in patients with impaired kidney function. This regulatory structure dictates that while acute symptoms are typically mild, the mandatory condition for any suspected overdose is to seek emergency medical attention for assessment of overall risk.

Therapeutic Uses of Ciprid

Main Uses and Benefits of Ciprid

Ciprid is a broad-spectrum antibiotic belonging to the fluoroquinolone class. It is primarily used to treat various bacterial infections by inhibiting the enzymes necessary for bacterial DNA replication and repair, thereby preventing the growth and spread of the infection.

Therapeutic Indications

This medication is indicated for the treatment of several types of infections caused by susceptible strains of bacteria. Common applications include:

  • Urinary Tract Infections (UTIs): It is effective against both uncomplicated and complicated infections of the bladder and kidneys.
  • Respiratory Tract Infections: It may be used for certain types of pneumonia, chronic bronchitis exacerbations, and acute sinusitis.
  • Skin and Soft Tissue Infections: It treats infections of the skin layers and underlying tissues.
  • Bone and Joint Infections: The medication can penetrate bone tissue, making it a treatment option for osteomyelitis.
  • Gastrointestinal and Intra-abdominal Infections: It is used for specific bacterial diarrheas, typhoid fever, and infections within the abdominal cavity.

Clinical Benefits

The primary benefit of Ciprid is its ability to target a wide range of Gram-negative and some Gram-positive bacteria. Its systemic absorption allows it to reach various tissues throughout the body, providing a versatile option for managing complex or deep-seated infections. By resolving the underlying bacterial colonization, the medication helps alleviate symptoms such as fever, inflammation, and pain associated with the infection.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Ciprid (Sucralfate)?

Ciprid's eligibility profile is strictly defined by regulatory documentation. The medication is primarily established for use in adult patients for the short-term treatment and maintenance of duodenal ulcers.

The drug is contraindicated and must not be used by patients with a known hypersensitivity to sucralfate or any of its components. Furthermore, the oral suspension formulation is strictly prohibited from intravenous administration due to the risk of severe complications.

Use with Caution is required for several populations. Patients with chronic renal failure or those on dialysis must use Ciprid cautiously due to the potential for aluminum accumulation and toxicity. Older adults also require careful consideration due to a higher frequency of decreased organ function. Safety and effectiveness have not been established for the pediatric population.

During pregnancy, Ciprid is classified as Category B and should be used only if clearly needed. Caution is also advised for nursing mothers as excretion into human milk is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Exposure-Modifying Interactions and Timing Rules

The official regulatory profile of Ciprid (Sucralfate) is defined by a non-systemic pharmacokinetic interaction rooted in its localized action. Sucralfate's physical binding in the gastrointestinal tract can significantly reduce the extent of absorption (bioavailability) for numerous co-administered oral medications. This outcome requires a mandatory administration separation to maintain therapeutic exposure. Regulatory labels stipulate that medications whose absorption is critical, such as Digoxin, Phenytoin, L-thyroxine, and Fluoroquinolone antibiotics, must be administered two hours prior to Sucralfate to mitigate this effect.


Additive Substance Risk

Co-administration with other aluminum-containing products (e.g., certain antacids) is documented to contribute to an increased total body burden of aluminum. This risk of accumulation and subsequent toxicity is heightened in patients with chronic renal failure or those on dialysis due to their impaired ability to excrete absorbed aluminum. No metabolic (CYP enzyme) or drug transporter-mediated interactions are documented in the primary regulatory labels.


Substance Incompatibilities

Regulatory documents also note a specific physical incompatibility with enteral (tube) feedings, which carries a documented risk of causing tube clogging.

Mechanism of Action

Selective Physical Barrier Formation

The primary action is a non-systemic physical mechanism strictly dependent on the presence of gastric acid ( pH < 4) for molecular activation. The molecule undergoes polymerization in this acidic environment, forming a viscous, anionic polymer that selectively adheres to exposed, positively charged proteins present at sites of mucosal injury. This creates a dense, physical barrier that mechanically insulates the tissue from aggressive luminal factors such as hydrochloric acid, the enzyme pepsin, and bile salts.

Localized Modulation of Cytoprotective Factors

The mechanical shielding results in the preservation and localized concentration of endogenous healing mediators by preventing their degradation or wash-out from the injury site. This indirect effect on the local microenvironment supports key factors, including locally secreted prostaglandins ( PGE2) and bicarbonate ions ( HCO3^-) . This stabilization of local defense mechanisms supports physiological processes of cellular repair by maintaining a stable microenvironment.

Mechanism Constraint: pH Dependency

The entire mechanistic cascade, from chemical activation to adhesive interaction, is strictly dependent on the presence of a gastric pH of 4 or lower. The mechanism is constrained by, and potentially inhibited in, physiological situations where the stomach pH is significantly elevated, as the necessary molecular cross-linking cannot occur.

Dosage and Administration Information

How Ciprid (Sucralfate) is Used

The administration of Ciprid follows standardized usage protocols to ensure its function as a mucosal protectant. Ciprid is for oral administration, utilizing the 1 gram tablet or the 1 gram per 10 mL oral suspension form.

Official Dosing and Scheduling

Standard dosing is set at 1 gram per dose. The frequency of administration depends on the clinical use pattern:

  • Active Treatment: The standard regimen involves four times daily (Q.I.D.) dosing, with a maximum total daily dose of 4 grams.
  • Maintenance Therapy: For the prevention of ulcer recurrence, the pattern is typically reduced to twice daily (B.I.D.) dosing.

Administration Conditions and Timing

Administration occurs on an empty stomach. For acute treatment, the timing is defined as approximately one hour before each meal and at bedtime. The usual course duration for active treatment is typically 4 to 8 weeks.

Procedural Constraints

The integrity of the administration schedule is important regarding drug separation. Ciprid is not taken concurrently with other oral medications or antacids to prevent interference with its localized action:

  • Antacids: Doses are separated by at least 30 minutes.
  • Other Oral Medications: Administration is separated by at least 2 hours.

Population Use Notes

Dosing is not established for pediatric patients. For older adults, dose selection is cautious due to potential physiological changes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciprid (Sucralfate)


Evidence for Active Duodenal and Gastric Ulcer Healing

The core research for Ciprid was used in research exploring how symptoms change over time and for studying the outcomes related to duodenal and gastric ulcers in the upper digestive tract. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted to assess ulcer closure over defined time intervals, typically four to eight weeks. Researchers measured the degree of ulcer closure, often confirmed by endoscopy, and examined patient-reported outcomes describing perceived discomfort, such as measurements of pain intensity.

Studies reported measurements showing duodenal ulcer closure when Ciprid was administered, and these measurements were examined in comparison to those reported for placebo groups. Early research describes patterns measured during the study period by comparing Ciprid to placebo or to older types of acid-reducing drugs. Results apply only to the populations studied and the specific conditions under which those trials were conducted.


Evidence for Preventing Ulcer Recurrence (Maintenance Therapy)

Ciprid was studied for its application in research contexts involving fluctuating or unstable symptoms, particularly exploring outcomes related to ulcer recurrence. This was primarily evaluated in long-term placebo-controlled trials that monitored adult patients whose ulcers were already stabilized. The main focus of these studies was to assess the Rate of Ulcer Recurrence over periods up to a year.

Similar to the acute closure trials, the evidence for maintenance therapy largely consists of studies conducted before H. pylori eradication became the standard of care for the management of recurrence. Therefore, these trials provide context but not individual predictions regarding recurrence management in the presence of current standards of care.


What is Still Uncertain in the Research

The research evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and certain areas require further investigation. Key limitations include the fact that much of the core evidence for ulcer management is older, meaning the studies were conducted without the benefit of current H. pylori management practices. Comparative evidence is lacking in some contexts, particularly head-to-head trials against the newest classes of ulcer treatments. Overall, the research provides context but not individual predictions about patient response, and subgroup findings are uncertain for many specialized populations.

Key Studies & References

  1. Sucralfate Oral Suspension: NIH DailyMed Drug Information (Non-Systemic Classification)
  2. Sucralfate Oral Tablets: NIH DailyMed Drug Label (Primary Therapeutic Indications)

Frequently Asked Questions (FAQ)

Common questions about Ciprid (FAQ)


Q: Can Ciprid be taken with common pain relievers like ibuprofen?

Regulatory documents advise that Ciprid should be separated from other oral medications to prevent interference with their absorption. This is because Ciprid creates a physical coating in the digestive tract. Official prescribing information indicates a required separation of at least 2 hours between taking Ciprid and taking other oral medications, including common pain relievers.


Q: Does Ciprid cause weight gain?

Weight gain is not listed among the commonly or infrequently reported adverse reactions in official prescribing information. The most frequent documented side effect of Ciprid is constipation. Concerns about weight changes are best discussed with a healthcare professional.


Q: Is Ciprid safe to use during pregnancy, according to official classification?

Ciprid (Sucralfate) is officially classified as Pregnancy Category B. This classification suggests that studies have generally not revealed evidence of fetal harm. Official documents advise that the medication should be used during pregnancy only if it is clearly needed.


Q: Can older adults typically use Ciprid?

Yes, older adults can use Ciprid, but official documentation advises a cautious approach when determining the dose. This is due to the greater frequency of decreased hepatic, renal, or cardiac function often observed in older adults.


Q: Can Ciprid be used while breastfeeding, according to official guidelines?

Official guidelines advise caution for nursing mothers. It is unknown whether Ciprid is excreted into human milk. Due to the minimal systemic absorption of the drug, the use of caution is advised, as excretion into human milk is unknown.


Q: Does Ciprid interact with birth control pills?

Official labels state that Ciprid can reduce the absorption of other oral medications due to its physical binding properties. While birth control pills are not explicitly named among the medications listed, the mandatory 2-hour separation rule applies to all oral medications whose absorption may be impacted, including those not explicitly listed on the label.


Q: Does Ciprid affect concentration or memory?

Official regulatory documents list several central nervous system effects, such as dizziness and insomnia, as infrequent adverse reactions. However, changes to concentration or memory are not explicitly listed in the primary regulatory sources as reported side effects.


Q: Are there different dosages of Ciprid, and what do they relate to?

Yes, official prescribing information details different dose frequencies. A higher frequency regimen is described for the short-term treatment of active ulcers. A reduced frequency regimen is described for maintenance therapy aimed at preventing ulcer recurrence.


Q: What is the official withdrawal or discontinuation advice for Ciprid?

Official patient information notes that discontinuation of the medication without consulting a prescriber is generally advised against. This recommendation applies even if the symptoms or ulcer pain are no longer felt, as the full treatment course is needed for healing.


Q: Is Ciprid the same type of medicine as [similar drug name]?

Ciprid (Sucralfate) is officially classified as an Antiulcer Agent and a Mucosal Protectant. This classification differentiates it from other drug classes, such as proton pump inhibitors (PPIs) or H2 blockers, which focus on reducing the amount of acid the stomach produces.


Q: How long does it usually take to feel the effects of Ciprid?

Official clinical trial data indicates that while healing may begin during the initial weeks of treatment, the full course for active ulcers is usually 4 to 8 weeks. Ciprid acts locally as a physical barrier and does not immediately stop pain in the way a pain reliever does.


Q: If I miss a dose of Ciprid, what does the official document say I should do?

Regulatory documents outline the procedure for a missed dose, which typically involves taking the dose if remembered soon after, or skipping it if near the next scheduled time. The information generally advises against taking two doses at the same time.


Q: How long does Ciprid stay in your system?

Official information states that Ciprid is only minimally absorbed from the gastrointestinal tract and acts primarily at the site of the ulcer. The small amount of the drug that is absorbed is mainly excreted rapidly via the urine.


Q: What is the difference between Ciprid and its generic version?

The brand-name medication Ciprid and its generic version contain the exact same active ingredient, which is Sucralfate. Generic and brand-name medications are considered chemically equivalent by the FDA and function in the body using the same mechanism.


Q: Can men and women use Ciprid in the same way?

The official prescribing information for Ciprid provides a standard oral dosage regimen that is consistent for all adults. It does not specify separate dosing or administration instructions based on the patient's sex.


Q: Is Ciprid considered a long-term or short-term treatment?

Ciprid has official indications for both. It is indicated for short-term treatment (up to 8 weeks) of active duodenal ulcers and is also used for maintenance therapy for the long-term prevention of ulcer recurrence at a lower frequency.


Q: Do studies suggest any potential for dependency with Ciprid?

Official pharmacological information indicates that because Ciprid is a localized mucosal protectant and is only minimally absorbed systemically, there is no known potential for dependence documented in the regulatory labels.


Q: Is there a patient leaflet available for Ciprid?

Yes, patient information leaflets (PILs) or medication guides are generally available for Ciprid (Sucralfate). These documents provide non-clinical usage, storage, safety, and disposal information for the public.


Q: What should I do if I suspect an interaction between Ciprid and another medicine?

If there is suspicion of an interaction, consulting with a healthcare professional or pharmacist is recommended, as they can evaluate potential effects and advise on next steps.


Q: When should I expect the side effects of Ciprid to lessen or go away?

Official patient safety information notes that some side effects, especially those common when starting a medication, may not require medical attention and can be expected to lessen or go away as your body adjusts to the medicine.


Q: Does Ciprid interact with a common supplement like Magnesium or Calcium?

Ciprid can decrease the effects of Calcium and Magnesium supplements due to its physical binding properties in the stomach. Official patient information indicates that a separation of at least 30 minutes between Ciprid and supplements containing these minerals is recommended.


Q: Is the evidence for Ciprid based on clinical trials?

Yes, the regulatory evidence supporting Ciprid’s effectiveness in healing ulcers is based on data collected from controlled clinical research. The primary evidence base consists of Randomized Controlled Trials (RCTs).


Q: Does Ciprid have a known expiration or shelf life?

Ciprid, like all medications, is subject to specific quality and safety checks which guarantee an effective product for a defined period. Official patient information advises that unused or expired Ciprid should be disposed of via an official medicine take-back program.


Q: What is the general expectation for improvement when using Ciprid?

Official documents state that the general expectation is for the ulcer to heal over the specified course of treatment. Studies reported measurements of ulcer closure over the treatment period, which is typically 4 to 8 weeks.


Q: Can Ciprid be taken with herbal remedies?

Official guidance advises patients to inform their doctor or pharmacist about all other medications, including herbs and vitamins. This is noted because Ciprid’s localized action has the potential to alter the absorption of other orally administered products.

How should Ciprid be stored and disposed of?

How to Store and Dispose of Ciprid (Sucralfate)

Ciprid (Sucralfate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C ( 68 F to 77 F), with excursions permitted up to 30 C. The medication must be protected from freezing. The container, especially the oral suspension, should be kept tightly closed and stored away from excess heat and moisture. As with all medicines, it must be kept out of the reach and sight of children.

For disposal, the medicine must not be flushed down the toilet. Unused or expired Ciprid should be discarded via an official medicine take-back program or the authorized household trash method, following regulatory guidelines for mixing the product with an unappealing substance before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciprid found in:

A-Z Index: